U.S. Emergency Contraceptive Pills Market Size, Share & Trends Analysis Report By Type (Combination Pills, Progesterone Pills, Ulipristal Acetate), By Distribution Channel (Retail Store, Online Store), By Region, And Segment Forecasts, 2023 - 2030

U.S. Emergency Contraceptive Pills Market Size, Share & Trends Analysis Report By Type (Combination Pills, Progesterone Pills, Ulipristal Acetate), By Distribution Channel (Retail Store, Online Store), By Region, And Segment Forecasts, 2023 - 2030


U.S. Emergency Contraceptive Pills Market Growth & Trends


The U.S. emergency contraceptive pills (ECPs) market size is expected to reach USD 5.1 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to grow at a CAGR of 5.24% from 2023 to 2030. The rising acceptance of ECPs among women of reproductive age is expected to drive the growth. As more women recognize the importance of emergency contraception and its effectiveness, the market is expected to witness further expansion to meet the increasing demand for accessible and reliable contraceptive options.

The market is anticipated to grow owing to the increasing incidence of unintended pregnancies. These pregnancies can adversely affect women's health, education, career, and family life. According to The National Survey of Family Growth, in 2017, 60.3% of women aged 20 to 44 years at risk of unintended pregnancy used effective contraceptive methods. This data highlights the need for reliable emergency contraception options, leading to the market's growth in response to the increasing demand from women who want to avoid unintended pregnancies.

Key players are implementing various strategies such as partnerships, mergers & acquisitions, expansions, and launching new products to expand their market presence. These strategic initiatives are expected to contribute to the market's growth. For instance, in April 2023, Foundation Consumer Healthcare, a private company manufacturing over-the-counter emergency contraceptive pills and healthcare products, is considering a potential sale worth 4 billion. The company gained prominence in 2017 when it acquired emergency contraception brands like Plan B One-Step from Teva Pharmaceutical Industries, based in Israel. This move contributed to the company's significant recognition in the market.

U.S. Emergency Contraceptive Pills Market Report Highlights

  • Based on type, the progesterone pills segment held the largest market share of over 45% in 2022, owing to the introduction of multiple products from various market players and a high success rate over other options
  • Based on distribution channel, the retail store segment held the largest revenue share of over 55% in 2022 during the forecast period. An increasing number of pharmacies in the U.S. that offers a diverse range of products from different market player is expected to drive the market growth
  • The online store segment is anticipated to witness the fastest growth during the forecast period. The increasing internet accessibility and growing awareness among women about emergency contraceptives in the U.S. are expected to fuel the segment's growth
  • The Southeast region held the largest market share in 2022, primarily due to the increasing prevalence of unplanned pregnancies
Please note The report will be delivered in 2-3 business days upon order notification.


Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Market Definitions
1.2. Estimates and Forecast Timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. GVR’s Internal Database
1.4.3. Secondary Sources & Third-Party Perspectives
1.4.4. Primary Research
1.5. Information Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Data Visualization
1.7. Model Details
1.7.1. Commodity Flow Analysis
1.8. List of Secondary Sources
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Trends and Outlook
3.3. Market Dynamics
3.3.1. Market Driver Analysis
3.3.1.1. Increasing awareness about emergency contraception methods
3.3.1.2. Rising prevalence of unintended pregnancies
3.3.1.3. Increased focus on women's health by the government and non-government organizations.
3.3.2. Market Restraint Analysis
3.3.2.1. Product recall
3.3.2.2. Adverse effects associated with the use of contraceptive drugs
3.4. Business Environment Analysis
3.4.1. PESTLE Analysis
3.4.2. Porter’s Five Forces Analysis
3.5. COVID-19 Impact Analysis
Chapter 4. Type Business Analysis
4.1. U.S. Emergency Contraceptive Pills Market: Type Movement Analysis & Market Share, 2022 & 2030
4.2. U.S. Emergency Contraceptive Pills Market: Segment Dashboard
4.3. Combination Pills
4.3.1. Combination Pills Market, 2018 - 2030 (USD Million)
4.4. Progesterone Pills
4.4.1. Progesterone Pills Market, 2018 - 2030 (USD Million)
4.5. Ulipristal Acetate
4.5.1. Ulipristal Acetate Market, 2018 - 2030 (USD Million)
Chapter 5. Distribution Channel Business Analysis
5.1. U.S. Emergency Contraceptive Pills Market: Distribution Channel Movement Analysis & Market Share, 2022 & 2030
5.2. U.S. Emergency Contraceptive Pills Market: Segment Dashboard
5.3. Retail Store
5.3.1. Retail Store Market, 2018 - 2030 (USD Million)
5.4. Online Store
5.4.1. Online Store Market, 2018 - 2030 (USD Million)
5.5. Others
5.5.1. Others Market, 2018 - 2030 (USD Million)
Chapter 6. Regional Business Analysis
6.1. U.S. Emergency Contraceptive Pills Market by Region, 2022 & 2030
6.2. Northeast
6.2.1. Northeast Market, 2018 - 2030 (USD Million)
6.3. Southeast
6.3.1. Southeast Market, 2018 - 2030 (USD Million)
6.4. Midwest
6.4.1. Midwest Market, 2018 - 2030 (USD Million)
6.5. West
6.5.1. West Market, 2018 - 2030 (USD Million)
6.6. Southwest
6.6.1. Southwest Market, 2018 - 2030 (USD Million)
Chapter 7. Competitive Landscape
7.1. Company Categorization
7.2. Strategy Mapping
7.2.1. Expansion
7.2.2. Acquisition
7.2.3. Collaborations
7.2.4. New Product Launches
7.2.5. Others
7.3. Company Profiles/Listing
7.3.1. Afaxys Pharma LLC
7.3.1.1. Overview
7.3.1.2. Financial Performance
7.3.1.3. Product Benchmarking
7.3.1.4. Strategic Initiatives
7.3.2. Teva Pharmaceutical Industries Ltd.
7.3.2.1. Overview
7.3.2.2. Financial Performance
7.3.2.3. Product Benchmarking
7.3.2.4. Strategic Initiatives
7.3.3. Syzygy Healthcare, LLC
7.3.3.1. Overview
7.3.3.2. Financial Performance
7.3.3.3. Product Benchmarking
7.3.3.4. Strategic Initiatives
7.3.4. Gedeon Richter USA, Inc.
7.3.4.1. Overview
7.3.4.2. Financial Performance
7.3.4.3. Product Benchmarking
7.3.4.4. Strategic Initiatives
7.3.5. Rapha Pharmaceuticals, Inc.
7.3.5.1. Overview
7.3.5.2. Financial Performance
7.3.5.3. Product Benchmarking
7.3.5.4. Strategic Initiatives
7.3.6. Perrigo Company plc.
7.3.6.1. Overview
7.3.6.2. Financial Performance
7.3.6.3. Product Benchmarking
7.3.6.4. Strategic Initiatives
7.3.7. Foundation Consumer Healthcare LLC
7.3.7.1. Overview
7.3.7.2. Financial Performance
7.3.7.3. Product Benchmarking
7.3.7.4. Strategic Initiatives
7.3.8. Wockhardt USA
7.3.8.1. Overview
7.3.8.2. Financial Performance
7.3.8.3. Product Benchmarking
7.3.8.4. Strategic Initiatives
7.3.9. Pfizer Inc.
7.3.9.1. Overview
7.3.9.2. Financial Performance
7.3.9.3. Product Benchmarking
7.3.9.4. Strategic Initiatives
7.3.10. Bayer plc
7.3.10.1. Overview
7.3.10.2. Financial Performance
7.3.10.3. Product Benchmarking
7.3.10.4. Strategic Initiatives

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings